FDA Hosts Public Workshop on Developing Antiviral Drugs for Immunocompromised Patients with Adenoviral Infections

Summary

The FDA is hosting a public workshop to discuss the development of antiviral drugs for treating adenoviral infections in immunocompromised patients, with the goal of gathering input from the public on scientific and clinical trial design considerations.